GW Pharmaceuticals (NASDAQ: GWPH) has come a long ways since gaining EU approval for Sativex, which treats muscle spasms in multiple sclerosis patients, but has been commercially disappointing with sales that would be a rounding error for many large biotechs. Here are five charts that show the current state of the biotech focused on making drugs from marijuana.
